Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study

2007 ◽  
Vol 23 (4) ◽  
pp. 286-291 ◽  
Author(s):  
L. Lazar ◽  
R. Ofan ◽  
N. Weintrob ◽  
A. Avron ◽  
M. Tamir ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Newly Diagnosed ◽  
Double Blind

β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1749-1753 ◽  
Author(s):  
Itamar Raz ◽  
Dana Elias ◽  
Ann Avron ◽  
Merana Tamir ◽  
Muriel Metzger ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Cell Function ◽  
Phase Ii Trial ◽  
Β Cell ◽  
Double Blind ◽  
Β Cell Function ◽  
New Onset

scholarly journals A rationally designed peptide IA-2-P2 against type 1 diabetes in streptozotocin-induced diabetic mice

2017 ◽  
Vol 14 (3) ◽  
pp. 184-190 ◽  
Author(s):  
Lili Shen ◽  
Shiping Lu ◽  
Dongcheng Huang ◽  
Guoliang Li ◽  
Kunfeng Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Type 1 Diabetes Mellitus ◽  
Rabbit Model ◽  
Immunological Tolerance ◽  
Heat Shock Protein 60 ◽  
P2 Peptide

Recent studies have investigated the potential of type 1 diabetes mellitus–related autoantigens, such as heat shock protein 60, to induce immunological tolerance or to suppress the immune response. A functional 24-residue peptide derived from heat shock protein 60 (P277) has shown anti-type 1 diabetes mellitus potential in experimental animals and in clinical studies, but it also carries a potential atherogenic effect. In this study, we have modified P277 to retain an anti-type 1 diabetes mellitus effect and minimize the atherogenic potential by replacing the P277 B epitope with another diabetes-associated autoantigen, insulinoma antigen-2 (IA-2), to create the fusion peptide IA-2-P2. In streptozotocin-induced diabetic C57BL/6J mice, the IA-2-P2 peptide displayed similar anti-diabetic effects to the control P277 peptide. Also, the IA-2-P2 peptide did not show atherogenic activity in a rabbit model. Our findings indicate the potential of IA-2-P2 as a promising vaccine against type 1 diabetes mellitus.

scholarly journals Effect of Photopheresis on Lymphocyte Population in Children with Newly Diagnosed Type 1 Diabetes

2004 ◽  
Vol 11 (5) ◽  
pp. 856-861 ◽  
Author(s):  
J. Ernerudh ◽  
J. Ludvigsson ◽  
G. Berlin ◽  
U. Samuelsson
Keyword(s):  
Type 1 Diabetes ◽  
Placebo Group ◽  
Lymphocyte Subsets ◽  
Randomized Study ◽  
Disease Process ◽  
Treated Group ◽  
Newly Diagnosed ◽  
Recent Infection ◽  
Double Blind

ABSTRACT In recent years photopheresis has been claimed to be an effective form of immunomodulation. It has also been shown to have an effect on the disease process at the onset of type 1 diabetes. In a double-blind, placebo-controlled randomized study, we analyzed if the effect of photopheresis in children with newly diagnosed diabetes is related to changes in the balance of lymhocyte populations. We also analyzed if lymphocyte subsets were related to recent infection, mild or aggressive disease manifestations, heredity, or gender. Nineteen children received active treatment with photopheresis, while 21 children received sham pheresis (placebo group). No influence of a history of previous infection, heredity, or certain clinical parameters on lymphocyte subsets was found. At the onset of type 1 diabetes, girls showed a higher proportion and a larger number of T cells (CD3+) and T-helper cells (CD4+) and a higher proportion of naïve CD4+CD45RA+ cells. In the placebo group, an increase in the number of subsets with the activated phenotype in both the CD4 (CD29+) and the CD8 (CD11a+) compartments was noted during the course of the study. These changes did not occur in the photopheresis group. No relation between lymphocyte subsets and clinical outcome was found 1 year after the treatment with photopheresis. In conclusion, we found no major effect of photopheresis on lymphocyte populations in a group of children with newly diagnosed type 1 diabetes. However, in the placebo group the proportions of activated CD4 and CD8 cells increased over time. Since these changes did not occur in the actively treated group, our findings suggest that photopheresis may have some suppressive effects.

Sign in / Sign up

Export Citation Format

Share Document